Related consultantsAll related consultants
In the Press
Innovations in the press
INTERNATIONAL CLINICAL TRIAL for brain cancer
Intra-operative radiotherapy (IORT) is a pioneering radiotherapy technique for patients with GBM (Glioblastoma Multiforme), a brain cancer with a high mortality rate.
The London Clinic is the first and currently only site in the UK to offer IORT for GBM, as part of the INTRAGO II phase 3 clinical trial, and one of 12 international hospitals taking part.
The INTRAGO II trial aims to bridge the inevitable gap between surgery and post-operative radiotherapy, and investigate the benefit of the treatment for glioblastoma, to help patients now and in the future.
For further information on the trial, or patient suitability please contact:
- Tel +44 (0)203 219 3315
NEURO INTRA-OPERATIVE RADIOTHERAPY (IORT)
IORT is delivered with the Carl Zeiss Intrabeam® system - a miniaturised X-ray device which is located within our on-site theatres. During surgery and after the tumour is removed, a high dose of radiotherapy is administered directly to the tumour cavity, aimed at clearing any microscopic disease which may have been left behind. Currently, IORT is only offered as part of a clinical, randomised phase 3 trial.
IORT removes the unnecessary delay in administering radiotherapy treatment to the patient. Radiotherapy is applied following surgery with patient under anaesthetic prior to closure. This technique is safe and allows local dose intensification.
WHAT IS GLIOBLASTOMA MULTIFORME (GBM)?
GBM is the most common malignant brain cancer, affecting roughly 2,000 adults every year in the UK, with figures predicted to rise over the years to come.
GBM is primarily treated with a combination of surgery, chemotherapy and external beam radiotherapy. Despite this, due to the high growth rate of cells there is a high chance the tumour can reoccur.
IORT shows great promise in the treatment of glioblastoma. At The London Clinic, a boost dose of up to 30Gy may be delivered, in addition to standard post operative radiotherapy, to better control the cancer cells left behind in the tumour bed, before any cells start to regrow.
Intrago ii, Phase 3 clinical TRIAL
INTRAGO II is an international, multi-centre phase 3, randomised trial. Patients are randomly allocated between two different trial groups. In one group, the patient will receive the standard care of treatment including radiotherapy and chemotherapy. In the other, the patient will receive the standard care with an additional boost of intra-operative radiotherapy (IORT) delivered during surgery. All patients are carefully followed-up to monitor their condition.
WHO CAN APPLY FOR THE CLINICAL TRIAL?
Patients who have a suspected GBM without any previous radiotherapy or chemotherapy, can be considered for the trial. Your doctor will advise you if you are suitable to take part in the INTRAGO II trial. Candidates must be aged 18 or older and younger than 80, and must not have had previous cranial radiotherapy.
WHY CONSIDER THE iort INTRAGO II TRIAL
- Administered during surgery
- Increased local dose
- Careful follow up on all patients
THE IORT SERVICE AT THE LONDON CLINIC
The London Clinic supports a comprehensive neurological service, incorporating high-spec linear accelerators for radiotherapy, stereotactic radiotherapy with CyberKnife™, a state-of-the-art intensive care unit (ICU) and a comprehensive rehabilitation and aftercare programme.
Consultant neurosurgeons, Professor Keyoumars Ashkan, Mr Ranj Bhangoo and Consultant Oncologist, Dr Matt Williams, are leading the clinical trial at The London Clinic, and are asking consultant oncologists and neurologists to refer patients for the clinical trial. Participation in this trial reflects our approach to research and innovation, and will provide patients a new treatment option for GBM.
Q&A: Prof Ashkan and Mr Bhangoo
Marylebone Journal, June 2019
Consultant neurosurgeons at The London Clinic on a highly promising clinical trial for a new brain cancer treatment.
FURTHER INFORMATION AND ENQUIRIES
For more information on our INTRAGO II phase 3 trial, please contact us via our online enquiry form or by calling +44 (0) 20 3219 3315
General enquiries: 020 7935 4444 Appointments: 020 7616 7693 Self-Pay: 020 3219 3315
Your call may be recorded for training and monitoring purposes.